A Re-Examination of Neoadjuvant Therapy for Thymic Tumors: A Long and Winding Road

Fenghao Yu,Zhitao Gu,Xuefei Zhang,Ning Xu,Xiuxiu Hao,Changlu Wang,Yizhuo Zhao,Teng Mao,Wentao Fang

DOI: https://doi.org/10.3390/cancers16091680

2024-04-27

Cancers

Abstract:For most patients with advanced thymic epithelial tumors (TETs), a complete resection is a strong indicator of a better prognosis. But sometimes, primary surgery is unsatisfactory, and preoperative therapy is needed to facilitate complete resection. Neoadjuvant chemotherapy is the most used form of preoperative therapy. But studies on neoadjuvant chemotherapy have included mainly patients with thymoma; its efficacy in patients with thymic carcinoma is less known. Neoadjuvant chemoradiation has also been explored in a few studies. Novel therapies such as immunotherapy and targeted therapy have shown efficacy in patients with recurrent/metastatic TETs as a second-line option; their role as preoperative therapy is still under investigation. In this review, we discuss the existing evidence on preoperative therapy and the insight it provides for current clinical practice and future studies.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to improve the rate of complete surgical resection (R0 resection) through neoadjuvant therapy in the treatment of thymic epithelial tumors (TETs), thereby improving the prognosis of patients. Specifically, the paper focuses on the following aspects:

1. **Importance of R0 Resection**: For most patients with advanced thymic epithelial tumors, complete resection is a strong prognostic indicator. However, sometimes the initial surgery cannot achieve satisfactory results and neoadjuvant therapy is required to promote complete resection.

2. **Current Situation of Neoadjuvant Chemotherapy**: Neoadjuvant chemotherapy is currently the most commonly used neoadjuvant treatment method. However, most studies have mainly focused on thymoma patients, and less is known about the effect on thymic carcinoma patients. In addition, neoadjuvant chemoradiotherapy has also been explored in a few studies.

3. **Application of New Therapies**: Immunotherapy and targeted therapy have shown efficacy in the second - line treatment of recurrent or metastatic TETs, but their role as neoadjuvant therapies is still under study.

4. **Limitations of Clinical Trials**: Due to the rarity of TETs, most studies on neoadjuvant therapy are retrospective, lacking control groups and having small sample sizes. This makes it difficult to directly compare the results of different studies.

5. **Future Directions**: The paper discusses the significance of existing evidence for current clinical practice and explores possible future treatment strategies, including combining different treatment modalities or adding new drugs to existing regimens.

In summary, this paper aims to re - evaluate the current evidence of neoadjuvant therapy and provide directions for future clinical research.